Answers are grounded in this paper and cite their sources.
Evaluates eugenol-loaded gel's antifungal activity in onychomycosis, suggesting potential clinical application.
Introduction: Onychomycosis is a serious nail condition primarily caused by Trichophyton rubrum. Eugenol, a natural phenolic compound with antifungal properties, serves as a safer treatment approach for onychomycosis, showing low aqueous solubility and volatility. Thus, the current study aimed to develop a eugenol-loaded transethosomal (TE) gel to enhance solubility, stability, and topical delivery. Materials and methods: The optimum dose of eugenol was determined using minimum inhibitory concentration. The optimum TE formulation comprises 95 mg soy lecithin, 5 mg surfactant, and 0.375 mg/mL eugenol. Vesicles were characterized for particle size, PDI, zeta potential, drug loading, and entrapment efficiency. A transethosomal gel was developed using 1% Carbopol-940 gel mixed with the TE suspension. The gel was further characterized for organoleptic properties, pH, viscosity, and spreadability. In vitro drug release and permeation studies were performed using dialysis membranes in PBS pH 7.4, for both the TEs and gel. The ex-situ permeation studies were performed using the excisional-skin model from mice, as a preliminary permeability model. Antifungal efficacy of the final formulation was evaluated against the standard fluconazole gel. Results: The optimized TEs exhibited a vesicle size of 146.5 nm, PDI of 0.594, and zeta potential of −13.91 mV with high entrapment efficiency. In vitro drug release and ex-situ permeation studies in PBS (pH 7.4) demonstrated a 15.74-fold increase in eugenol solubility. Release kinetic model analysis showed that the final formulation followed the Peppas-Sahlin diffusion-dependent release model. The gel exhibited pseudoplastic rheology with high mechanical strength and ease of application. Drug release reached 72.84 ± 0.175% within 12 h, with a flux of 0.041 mg/cm²/h and a permeability coefficient of 9.2 × 10⁻⁵ m/s, confirming sustained and improved permeation through skin. Antifungal evaluation showed a zone of inhibition of 35.32 ± 0.57 mm, comparable to fluconazole gel (34.59 ± 0.56 mm). Discussion: The 15.74-fold increase in eugenol solubility (p < 0.001) confirms the formulation’s efficiency in enhancing aqueous solubility. The Peppas–Sahlin model indicates probability of diffusion-driven release with polymer relaxation, while the gel’s pseudoplastic nature and mechanical strength support easy topical application. The sustained release for 12-hour (∼73%) with moderate flux and permeability demonstrates statistically significant skin permeation compared to pure eugenol (p < 0.01) through skin. While statistically insignificant difference between fluconazole and TE gel (p > 0.05) suggests comparable antifungal efficacy. Conclusion: In comparison to fluconazole, the developed transethosomal gel possess improved eugenol solubility, sustained drug release, and antifungal activity. These findings suggest that the formulation may serve as a promising natural topical delivery system with potential application in the management of onychomycosis, although further studies using nail permeation models are required.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: